ONI, an Oxford-based maker of compact super-resolution microscopes, is in a sales-led growth phase: most current hiring is commercial, focused on capital-equipment sales and a push into the bioprocessing market, with roles in the United States and Peru. The engineering side pairs C++ and Python instrument software with a modern React/TypeScript/Next.js front end, aimed at automating imaging and making analysis usable by non-specialists.
ONI is a privately held biotechnology instrument company founded in 2016 and headquartered in Oxford, UK, with 51–200 employees. Its flagship product, the Nanoimager, is a desktop-scale super-resolution microscope for visualizing proteins, DNA and RNA in samples ranging from nanoparticles and viruses to cells and tissue. Core techniques include dSTORM, PALM, single-molecule FRET, single-particle tracking and TIRF imaging. The company sells to researchers and runs its commercial operation on Salesforce and HubSpot, with SolidWorks and 3DXperience supporting hardware design.
ONI uses C++ and Python alongside a React, TypeScript, Next.js and GraphQL front end, Salesforce and HubSpot for CRM, Tableau and Looker for analytics, and SolidWorks with 3DXperience for hardware design.
Yes. Sales is the dominant hiring focus at ONI, with hiring accelerating and roles posted in the United States and Peru, alongside smaller engineering, support and HR openings.
ONI is building a bioprocessing market strategy, expanding partnerships and business development, automating super-resolution microscopy, and simplifying image analysis for non-expert scientists.
Other companies in the same industry, closest in size
ONI's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.
